Imipenem (MK-0787), a new carbapenem antibiotic, combined with cilastatin sodium (MK-0791), was studied clinically and microbiologically. The following results were obtained: Concentrations of MK-0787 in the plasma and internal genital tissues were measured at 1 hour after an intravenous drip infusion of MK-0787/MK-0791 (500 mg/500 mg) for 30 minutes. Mean plasma levels higher than 11.8 micrograms/ml and mean tissue levels higher than 2.3 micrograms/g were observed. When its MIC values are considered, MK-0787/MK-0791 appeared to be bactericidal against many Gram-positive and Gram-negative bacteria except some Pseudomonas sp. and Enterococcus faecium. Clinical effects of the therapy with MK-0787/MK-0791 (500 mg/500 mg) using a drip infusion twice daily were evaluated in 3 patients with pyometra and 3 patients with Bartholin's gland abscess. Clinical responses were good in 5 of the 6 patients. One patient with pyometra due to E. coli didn't respond to the therapy. No side effects or abnormal laboratory findings due to the drug were noted.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Clinical applications and research progress of totally implantable venous access ports: a literature review.
Front Oncol
January 2025
Department of Anesthesiology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
Totally implantable venous access port (TIVAP), a novel intravenous infusion system that is used for long-term intravenous treatment, has become increasingly popular among cancer patients undergoing chemotherapy and other patients requiring long-term intravenous infusions. This technology has been introduced into clinical practice in China, with successful results. Nevertheless, there are still certain problems; for instance, China has not set up a specialized regulatory agency to oversee research and set guidelines for the comprehensive life-cycle management of TIVAP.
View Article and Find Full Text PDFPharmacokinetics and absorption, distribution, metabolism and excretion profiling of tanimilast following an intravenous C-microtracer coadministered with an inhaled dose in healthy male individuals.
Drug Metab Dispos
January 2025
Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy.
Tanimilast is an inhaled phosphodiesterase-4 inhibitor currently in phase III clinical development for treating chronic obstructive pulmonary disease and asthma. This trial aimed to characterize the pharmacokinetics, mass balance, and metabolite profiling of tanimilast. Eight healthy male volunteers received a single dose of nonradiolabeled tanimilast via powder inhaler (Chiesi NEXThaler [3200 μg]), followed by a concomitant intravenous infusion of a microtracer ([C]-tanimilast: 18.
View Article and Find Full Text PDFMulticentre, double-blind, randomised controlled clinical trial comparing intermittent cefoxitin administration versus loading bolus followed by continuous infusion for the prevention of surgical site infection in colorectal surgery: the PROPHYLOXITIN study protocol.
BMJ Open
January 2025
Université de Poitiers, INSERM U1070 PHAR2, CHU de Poitiers, Service d'Anesthésie-Réanimation et Médecine Péri-Opératoire, Poitiers, France
Introduction: Surgical site infections (SSIs) are the second leading cause of healthcare-associated infections in Europe with the highest rates being reported in colorectal surgery (ranging from 9% to 30%). Surgical antibiotic prophylaxis (SAP) is one of the most efficient measures for SSI prevention and should be started before surgical incision. Cefoxitin is an antibiotic widely used as SAP for colorectal surgery, but its continuous administration is currently the subject of debate due to its potential pharmacokinetic advantages.
View Article and Find Full Text PDFMothers' experiences as legal guardian of children's phlebitis during hospitalization in Indonesia: A phenomenological study.
Belitung Nurs J
January 2025
STIKes Mitra Keluarga, West Java, Indonesia.
Background: Peripheral intravenous catheter (PIVC) insertion is a common procedure performed by nurses for hospitalized children, but phlebitis-an inflammation of the vein-is a frequent complication. The response of the mother, as the child's primary caregiver, plays a key role in the healing process when phlebitis occurs.
Objective: This study aimed to explore mothers' experiences and perceptions regarding the occurrence and management of phlebitis in their children during hospitalization.
The prognosis for patients with acute promyelocytic leukemia (APL) has improved dramatically since the introduction of all-trans retinoic acid (ATRA) and intravenous arsenic trioxide (ATO). However, ATO administration requires daily infusions over several months, representing an onerous burden for hospitals and patients. We evaluated the bioavailability of a novel encapsulated oral ATO formulation in APL patients in first complete remission during standard-of-care consolidation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!